• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 3. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 4. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 5. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Diphenylmethanes

Sobetirome: A Comprehensive Overview

Sobetirome, also known by its CAS number 211110-63-3, is a compound that has garnered significant attention in the field of pharmacology and medical research. This compound is primarily recognized for its potential therapeutic applications in various medical conditions, particularly those related to metabolic disorders and cardiovascular health. Recent studies have shed light on its unique mechanisms of action and its potential to address unmet medical needs.

Sobetirome is a synthetic derivative of a naturally occurring metabolite, which has been extensively studied for its ability to modulate key pathways involved in lipid metabolism and energy homeostasis. The compound's structure has been optimized to enhance its bioavailability and efficacy, making it a promising candidate for therapeutic interventions. Researchers have demonstrated that Sobetirome exhibits potent effects on reducing low-density lipoprotein (LDL) cholesterol levels, which is a critical factor in the prevention of cardiovascular diseases.

The development of Sobetirome was driven by the need for novel agents that can effectively manage dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. Traditional therapies, such as statins, have been the mainstay of treatment; however, they are not suitable for all patients due to side effects or limited efficacy. Sobetirome, on the other hand, offers a different mechanism of action by targeting the liver's ability to produce cholesterol. This approach has shown promise in clinical trials, where it demonstrated significant reductions in LDL cholesterol levels without major adverse effects.

Recent advancements in the understanding of Sobetirome's pharmacokinetics have further enhanced its potential as a therapeutic agent. Studies have shown that the compound is well-absorbed orally and has a favorable safety profile, with minimal off-target effects. These findings are particularly encouraging for patients who are unable to tolerate conventional lipid-lowering medications.

One of the most exciting aspects of Sobetirome research is its potential application beyond dyslipidemia. Preclinical studies suggest that it may also play a role in managing other metabolic disorders, such as obesity and type 2 diabetes. By modulating pathways involved in energy expenditure and glucose metabolism, Sobetirome could offer a multifaceted approach to addressing these conditions.

The clinical development of Sobetirome has been rapid, with several phase II and III trials completed or underway. These trials have provided robust evidence supporting its efficacy and safety profile. Regulatory agencies have expressed interest in advancing this compound towards approval, which could pave the way for its widespread use in clinical practice.

In conclusion, Sobetirome (CAS No. 211110-63-3) represents a significant advancement in the field of lipid metabolism and metabolic disease management. With its unique mechanism of action, favorable safety profile, and potential for treating multiple conditions, it holds great promise for improving patient outcomes. As research continues to unfold, Sobetirome may become an essential tool in the fight against cardiovascular diseases and other metabolic disorders.

• 253329-34-9(Acetic acid,[4-[(2,4-dimethoxyphenyl)[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-)
• 565452-43-9(Acetic acid,[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-dimethylphenoxy]-)
• 913359-24-7(Acetic acid, [4-[bis(4-hydroxy-3,5-dimethylphenyl)methyl]phenoxy]-)
• 922169-89-9(Acetic acid, 2-[4-[bis(4-hydroxy-2,5-dimethylphenyl)methyl]phenoxy]-)
• 136157-98-7(O(1),O(3)-BIS(CARBOXYMETHYL)-O(2),O(4)-DIMETHYL-P-T-BUTYLCALIX(4)ARENE)
• 113215-72-8(4-tert-butylcalix[4]arene tetraacetic acid)
• 19728-20-2(2-2-methyl-5-(propan-2-yl)phenoxyacetic Acid)
• 5333-40-4((2-Isopropyl-5-methylphenoxy)acetic acid)
• 25141-58-6(2-Isopropylphenoxy Acetic Acid)
• 656260-08-1(Acetic acid,[4-[[4-hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]-)